Clinical characteristics, according to ELN2017 genetic-risk group, of patients with AML who underwent allogeneic HSCT
| Characteristics . | All (N = 234) . | ELN2017 favorable (n = 93) . | ELN2017 intermediate (n = 30) . | ELN2017 adverse (n = 111) . | P* . |
|---|---|---|---|---|---|
| Age at diagnosis, y | .01 | ||||
| Median | 59.9 | 55.1 | 60.8 | 62.7 | |
| Range | 14.3-75.8 | 14.3-73.9 | 19.2-72.2 | 20.0-75.8 | |
| Sex, n (%) | .33 | ||||
| Female | 116 (49.6) | 48 (51.6) | 11 (36.7) | 57 (51.4) | |
| Male | 118 (50.4) | 45 (48.4) | 19 (63.3) | 54 (48.6) | |
| WBC at diagnosis, ×109/L | <.001 | ||||
| Median | 6.9 | 15.8 | 2.5 | 4.7 | |
| Range | 0.7-385 | 1-324 | 0.7-146 | 0.7-385 | |
| Platelets at diagnosis, ×109/L | .49 | ||||
| Median | 66.5 | 75 | 77 | 60.5 | |
| Range | 3-950 | 3-238 | 10-268 | 3-950 | |
| Hemoglobin at diagnosis, g/dL | .43 | ||||
| Median | 8.8 | 8.9 | 9.2 | 8.2 | |
| Range | 4.2-14.9 | 4.3-14.7 | 5.2-13.4 | 4.2-14.9 | |
| Peripheral blasts at diagnosis, % | .32 | ||||
| Median | 26 | 32 | 14 | 22 | |
| Range | 0-97 | 2-97 | 1-96 | 0-97 | |
| Bone marrow blasts at diagnosis, % | .73 | ||||
| Median | 50 | 53.7 | 51 | 50 | |
| Range | 3-100 | 20-100 | 21-95 | 3-95 | |
| NPM1 mutation at diagnosis, n (%) | <.001 | ||||
| Absent | 162 (71.4) | 25 (28.7) | 27 (90.0) | 110 (100) | |
| Present | 65 (28.6) | 62 (71.3) | 3 (10.0) | 0 (0) | |
| FLT3-ITD mutation at diagnosis, n (%) | .41 | ||||
| Absent | 191 (84.1) | 73 (83.9) | 23 (76.7) | 95 (86.4) | |
| Present | 36 (15.9) | 14 (16.1) | 7 (23.3) | 15 (13.6) | |
| DNMT3A mutation at diagnosis, n (%) | .07 | ||||
| Absent | 112 (84.8) | 36 (75.0) | 25 (89.3) | 51 (91.1) | |
| Present | 20 (15.2) | 12 (25.0) | 3 (10.7) | 5 (8.9) | |
| FLT3-TKD mutation at diagnosis, n (%) | .09 | ||||
| Absent | 195 (89.0) | 69 (83.1) | 29 (96.7) | 97 (91.5) | |
| Present | 24 (11.0) | 14 (16.9) | 1 (0.3) | 9 (8.5) | |
| JAK2 mutation at diagnosis, n (%) | .008 | ||||
| Absent | 98 (92.5) | 26 (100.0) | 23 (79.3) | 49 (96.1) | |
| Present | 8 (7.5) | 0 (0.0) | 6 (20.7) | 2 (1.9) | |
| EVI1 expression at diagnosis, n (%) | <.001 | ||||
| Absent | 98 (77.8) | 44 (95.7) | 15 (71.4) | 39 (66.1) | |
| Present | 28 (22.2) | 2 (4.3) | 6 (28.6) | 20 (33.9) | |
| Remission status at HSCT, n (%) | .03 | ||||
| CR | 170 (74.9) | 73 (80.2) | 25 (83.3) | 72 (67.9) | |
| CR, MRD− | 47 (27.6) | 27 (37.0) | 7 (28.0) | 13 (18.1) | |
| CR, MRD+ | 24 (14.1) | 16 (21.9) | 4 (16.0) | 4 (5.6) | |
| CR, no information on MRD | 99 (58.2) | 30 (41.1) | 14 (56.0) | 55 (76.4) | |
| CRi | 34 (15.0) | 14 (15.4) | 1 (3.3) | 19 (17.9) | |
| PR | 23 (10.1) | 4 (4.4) | 4 (13.3) | 15 (14.2) | |
| Chemotherapy cycles before HSCT, n (%) | .09 | ||||
| 1 | 44 (25.6) | 12 (17.6) | 6 (23.1) | 26 (33.3) | |
| 2 | 97 (56.4) | 38 (55.9) | 16 (61.5) | 43 (55.1) | |
| ≥3 | 31 (18.0) | 18 (26.5) | 4 (15.4) | 9 (11.5) |
| Characteristics . | All (N = 234) . | ELN2017 favorable (n = 93) . | ELN2017 intermediate (n = 30) . | ELN2017 adverse (n = 111) . | P* . |
|---|---|---|---|---|---|
| Age at diagnosis, y | .01 | ||||
| Median | 59.9 | 55.1 | 60.8 | 62.7 | |
| Range | 14.3-75.8 | 14.3-73.9 | 19.2-72.2 | 20.0-75.8 | |
| Sex, n (%) | .33 | ||||
| Female | 116 (49.6) | 48 (51.6) | 11 (36.7) | 57 (51.4) | |
| Male | 118 (50.4) | 45 (48.4) | 19 (63.3) | 54 (48.6) | |
| WBC at diagnosis, ×109/L | <.001 | ||||
| Median | 6.9 | 15.8 | 2.5 | 4.7 | |
| Range | 0.7-385 | 1-324 | 0.7-146 | 0.7-385 | |
| Platelets at diagnosis, ×109/L | .49 | ||||
| Median | 66.5 | 75 | 77 | 60.5 | |
| Range | 3-950 | 3-238 | 10-268 | 3-950 | |
| Hemoglobin at diagnosis, g/dL | .43 | ||||
| Median | 8.8 | 8.9 | 9.2 | 8.2 | |
| Range | 4.2-14.9 | 4.3-14.7 | 5.2-13.4 | 4.2-14.9 | |
| Peripheral blasts at diagnosis, % | .32 | ||||
| Median | 26 | 32 | 14 | 22 | |
| Range | 0-97 | 2-97 | 1-96 | 0-97 | |
| Bone marrow blasts at diagnosis, % | .73 | ||||
| Median | 50 | 53.7 | 51 | 50 | |
| Range | 3-100 | 20-100 | 21-95 | 3-95 | |
| NPM1 mutation at diagnosis, n (%) | <.001 | ||||
| Absent | 162 (71.4) | 25 (28.7) | 27 (90.0) | 110 (100) | |
| Present | 65 (28.6) | 62 (71.3) | 3 (10.0) | 0 (0) | |
| FLT3-ITD mutation at diagnosis, n (%) | .41 | ||||
| Absent | 191 (84.1) | 73 (83.9) | 23 (76.7) | 95 (86.4) | |
| Present | 36 (15.9) | 14 (16.1) | 7 (23.3) | 15 (13.6) | |
| DNMT3A mutation at diagnosis, n (%) | .07 | ||||
| Absent | 112 (84.8) | 36 (75.0) | 25 (89.3) | 51 (91.1) | |
| Present | 20 (15.2) | 12 (25.0) | 3 (10.7) | 5 (8.9) | |
| FLT3-TKD mutation at diagnosis, n (%) | .09 | ||||
| Absent | 195 (89.0) | 69 (83.1) | 29 (96.7) | 97 (91.5) | |
| Present | 24 (11.0) | 14 (16.9) | 1 (0.3) | 9 (8.5) | |
| JAK2 mutation at diagnosis, n (%) | .008 | ||||
| Absent | 98 (92.5) | 26 (100.0) | 23 (79.3) | 49 (96.1) | |
| Present | 8 (7.5) | 0 (0.0) | 6 (20.7) | 2 (1.9) | |
| EVI1 expression at diagnosis, n (%) | <.001 | ||||
| Absent | 98 (77.8) | 44 (95.7) | 15 (71.4) | 39 (66.1) | |
| Present | 28 (22.2) | 2 (4.3) | 6 (28.6) | 20 (33.9) | |
| Remission status at HSCT, n (%) | .03 | ||||
| CR | 170 (74.9) | 73 (80.2) | 25 (83.3) | 72 (67.9) | |
| CR, MRD− | 47 (27.6) | 27 (37.0) | 7 (28.0) | 13 (18.1) | |
| CR, MRD+ | 24 (14.1) | 16 (21.9) | 4 (16.0) | 4 (5.6) | |
| CR, no information on MRD | 99 (58.2) | 30 (41.1) | 14 (56.0) | 55 (76.4) | |
| CRi | 34 (15.0) | 14 (15.4) | 1 (3.3) | 19 (17.9) | |
| PR | 23 (10.1) | 4 (4.4) | 4 (13.3) | 15 (14.2) | |
| Chemotherapy cycles before HSCT, n (%) | .09 | ||||
| 1 | 44 (25.6) | 12 (17.6) | 6 (23.1) | 26 (33.3) | |
| 2 | 97 (56.4) | 38 (55.9) | 16 (61.5) | 43 (55.1) | |
| ≥3 | 31 (18.0) | 18 (26.5) | 4 (15.4) | 9 (11.5) |
EVI1, ecotropic viral integration site-1; TKD, tyrosine kinase domain; WBC, white blood cell.
P values are from Fisher’s exact or Kruskal-Wallis test and compare the 3 ELN2017 genetic-risk groups.